SCHEMBL4121679

SCHEMBL4121679

CC(C)Oc1cc2ccccc2cc1C=C1SC(Nc2cccc(CC(=O)O)c2)=NC1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 1/20 0.37
CYSLTR1 Q9Y271 1/20 0.36
PTP4A3 O75365 1/20 0.36
PPARD Q03181 2/20 0.35
NR1H4 Q96RI1 2/20 0.35
PPARG P37231 1/20 0.35
PPARA Q07869 1/20 0.35
MAPT P10636 4/20 0.35
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
KDM4E B2RXH2 2/20 0.35
RECQL P46063 2/20 0.35
TDP1 Q9NUW8 2/20 0.35
NSD2 O96028 1/20 0.35
POLB P06746 1/20 0.35
APEX1 P27695 1/20 0.35
CTDSP1 Q9GZU7 1/20 0.35
P2RX3 P56373 2/20 0.35
S1PR1 P21453 1/20 0.35
ALDH1A1 P00352 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4121677 1.00 PDE5A (0.37) PDE5ACYSLTR1PTP4A3PPARDNR1H4
SCHEMBL4128924 0.91 S1PR1 (0.43) PTP4A3NR1H4MAPTMEN1KMT2A
SCHEMBL4128926 0.91 S1PR1 (0.43) PTP4A3NR1H4MAPTMEN1KMT2A
SCHEMBL4133682 0.88 PTP4A3 (0.49) PDE5APTP4A3PPARDNR1H4PPARG
SCHEMBL4133685 0.88 PTP4A3 (0.49) PDE5APTP4A3PPARDNR1H4PPARG
SCHEMBL4125733 0.80 PTP4A3 (0.50) PTP4A3MEN1KMT2AKDM4ETDP1
SCHEMBL4125736 0.80 PTP4A3 (0.50) PTP4A3MEN1KMT2AKDM4ETDP1
SCHEMBL4137478 0.79 MAPT (0.34) PTP4A3MAPTMEN1KMT2AKDM4E
SCHEMBL4137480 0.79 MAPT (0.34) PTP4A3MAPTMEN1KMT2AKDM4E
SCHEMBL4127749 0.79 KMT2A (0.46) PTP4A3NR1H4MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP claimed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ PDE5A 249/4885CYSLTR1 2909/4885PTP4A3 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.